復宏漢霖-B(02696.HK)實體瘤藥3期臨牀試驗申請獲批
復宏漢霖-B(02696.HK)公佈,自主開發的漢斯狀(斯魯利單抗注射液)聯合化療同步放療用於侷限期小細胞肺癌(LS-SCLC)治療的3期臨牀試驗申請獲國家藥監局批準。
公司擬在既往未接受過治療的侷限期小細胞肺癌(LS-SCLC)患者中開展國際多中心3期臨牀研究,以確證漢斯狀聯合化療同步放療的臨牀有效性和安全性。
公司指,漢斯狀爲其自主開發的創新型抗PD-1單抗,計劃用於多種實體瘤治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.